Centiva Capital LP Buys Shares of 6,664 Zoetis Inc. (NYSE:ZTS)

Centiva Capital LP purchased a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 6,664 shares of the company's stock, valued at approximately $1,086,000.

Other institutional investors have also modified their holdings of the company. Atlantic Edge Private Wealth Management LLC boosted its position in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 140 shares in the last quarter. Rakuten Securities Inc. boosted its holdings in Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after buying an additional 166 shares in the last quarter. Navigoe LLC acquired a new stake in Zoetis during the fourth quarter valued at $30,000. Murphy & Mullick Capital Management Corp acquired a new position in shares of Zoetis in the fourth quarter worth about $44,000. Finally, Asset Planning Inc purchased a new stake in shares of Zoetis during the 4th quarter worth about $58,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

Shares of Zoetis stock traded down $1.73 on Friday, hitting $159.96. 4,243,109 shares of the company were exchanged, compared to its average volume of 2,492,973. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a 50-day moving average price of $157.27 and a 200 day moving average price of $166.06. The stock has a market capitalization of $71.37 billion, a price-to-earnings ratio of 29.24, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm's quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.38 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company's stock, valued at $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock worth $312,254 in the last ninety days. 0.18% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ZTS. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Stifel Nicolaus reduced their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Morgan Stanley reduced their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Finally, Piper Sandler lifted their target price on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Zoetis presently has an average rating of "Buy" and an average target price of $212.13.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.